Picton Mahoney Asset Management’s Frazier Lifesciences Acquisition Corporation Warrant FLACW Stock Holding History

Picton Mahoney Asset Management’s Portfolio FLACW Stock Details FLACW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-33,332	Closed	-$21K	–	1182
2021 Q4	$21K	Hold	33,332	–	–	﹤0.01%	924
2021 Q3	$23K	Hold	33,332	–	–	﹤0.01%	835
2021 Q2	$36K	Buy	+33,332	New	+$33.3K	﹤0.01%	821

Other funds holding FLACW

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

EAM

Exos Asset Management New York $2.32K AUM 108.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return

Governors Lane New York $1.56B AUM 30.44% 1-Year Est. Return

Picton Mahoney Asset Management's FLACW Position: Q1 2022 in Review

Picton Mahoney Asset Management sold out of Frazier Lifesciences Acquisition Corporation Warrant (FLACW) in Q1 2022, closing a stake of 33,332 shares — an estimated $21K sold.

Picton Mahoney Asset Management first reported a position in FLACW in Q2 2021 and held it in 3 quarters. The position peaked at $36K in Q2 2021. 30 funds tracked by Wall St. Rank hold FLACW as of Q1 2022.

Picton Mahoney Asset Management reported no remaining Frazier Lifesciences Acquisition Corporation Warrant position as of Q1 2022 after selling out during the quarter.
Picton Mahoney Asset Management sold 33,332 Frazier Lifesciences Acquisition Corporation Warrant shares in Q1 2022, an estimated $21K.
Picton Mahoney Asset Management first reported a position in Frazier Lifesciences Acquisition Corporation Warrant in Q2 2021 and held it in 3 quarters.
Picton Mahoney Asset Management's Frazier Lifesciences Acquisition Corporation Warrant position peaked at $36K in Q2 2021.
30 funds tracked by Wall St. Rank held Frazier Lifesciences Acquisition Corporation Warrant as of Q1 2022.

Based on Picton Mahoney Asset Management's 13F filing for Q1 2022, filed 11 May 2022.